30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

First U.S. Patients Receive Agili-C Implants -

CartiHeal announced successful enrollment of the first two U.S. patients in the Agili-C™ Investigational Device Exemption pivotal study. The study received FDA approval at the end of 2016. To date, in Europe and Israel, 80 patients have been enrolled and treated. The trial's objective is to demonstrate superiority of the Agili-C implant vs. microfracture and debridement for the treatment of cartilage or osteochondral defects, in both arthritic knees and knees without degenerative changes. (CartiHeal, 8/17/18)